EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

The Efficacy and Safety of Botulinum Neurotoxin Type A in Treating Chronic Low Back Pain: A Systematic Review, Meta‐Analysis, Trial Sequential Analysis, and Meta‐Regression

Waseem Wagrees iD, Hesham Kelani, Hazem Mohamed Salamah, Abdelrahman Mahmoud, Yehya Khlidj, Mohamed R Abdelraouf, Bahaa Sharaf, Moustafa Elnewishy, Nadia Albaramony, Ahmed Naeem, Ahmed Abd Elazim, Mohammad El-Ghanem und 6 weitere

European Journal of Pain · 2025-04 · 29 (4)

DOI: 10.1002/ejp.4796 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Pain, online erschienen am 21.02.2025. Verfasst von Waseem Wagrees und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, School of Medicine, University of New Mexico, Albuquerque, New Mexico, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Low Back Pain, Chronic Pain, Neuromuscular Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic low back pain (CLBP) is a leading cause of disability. Botulinum neurotoxin type A (BoNT‐A) has strong anti‐spasmodic and analgesic effects, suggesting that its local muscular injection can reduce CLBP compared to other therapies. In this systematic review and meta‐analysis, we investigated the efficacy and safety of BoNT‐A on patients with CLBP.

Methods

We searched PubMed, Scopus, Cochrane, and Web of Science databases for studies comparing BoNT‐A to other therapies in terms of functional improvement and pain improvement as measured by visual analog scale (VAS) and clinically significant improvement in pain (50% or greater reduction in VAS score). We employed trial sequential analysis (TSA) to confirm the findings. The GRADE approach was employed to assess the overall quality of the evidence.

Results

The search yielded nine studies, seven randomised clinical trials (RCTs), and two prospective observational studies. Compared to the control, BoNT‐A increased the incidence of clinically significant improvement in pain (RR = 4.82, 95% CI (3.00, 7.76), p < 0.00001) and functional improvement (RR = 3.81, 95% CI (2.40, 6.04), p < 0.00001) (low‐certainty evidence), and reduced VAS score (MD = −1.62, 95% CI (−3.13, −0.11), p = 0.04) (very low‐certainty evidence). Subgroup analysis showed that BoNT‐A is effective against normal saline (moderate‐certainty evidence), and it was comparable to steroids and local anaesthetics (very low‐certainty evidence). TSA confirmed the findings regarding clinical improvement in pain and functional improvement.

Conclusion

BoNT‐A is a tolerable and effective treatment for CLBP with a longer duration of action. Future high‐quality studies are needed to confirm our findings. Significance This paper provides good evidence that BoNT‐A may be employed in patients suffering from resistant chronic low back pain not responding to normal saline injection due to its higher efficacy and longer duration of action. Compared to steroids and local anaesthetics injections, there is not enough data to draw a firm conclusion and future studies are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ALow Back PainChronic PainNeuromuscular AgentsHumansTreatment OutcomeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

BoNT‐Aback painbotulinum neurotoxinchronic painmeta‐analysis

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Department of Neurology, School of Medicine, University of New Mexico, Albuquerque, New Mexico, USA.
  • Department of Neurology, SUNY Downstate Health Sciences University at One Brooklyn Health, Brooklyn, New York, USA.
  • Faculty of Medicine, Zagazig University, Zagazig, Egypt.
  • Faculty of Medicine, Minia University, Minia, Egypt.
  • Faculty of Medicine, University of Algiers, Algiers, Algeria.
  • Faculty of Medicine, Alexandria University, Alexandria, Egypt.

ORCID-Profile: Waseem Wagrees

Zitieren

APA

Wagrees, W., Kelani, H., Salamah, H. M., Mahmoud, A., Khlidj, Y., Abdelraouf, M. R., Sharaf, B., Elnewishy, M., Albaramony, N., Naeem, A., Elazim, A. A., El-Ghanem, M., Greene-Chandos, D., Jadidi, M., Lerner, D. P., Kay, A. D., Merlin, L. R., & Brock, C. (2025). The Efficacy and Safety of Botulinum Neurotoxin Type A in Treating Chronic Low Back Pain: A Systematic Review, Meta‐Analysis, Trial Sequential Analysis, and Meta‐Regression. European Journal of Pain, 29(4). https://doi.org/10.1002/ejp.4796

Vancouver

Wagrees W, Kelani H, Salamah HM, Mahmoud A, Khlidj Y, Abdelraouf MR, et al. The Efficacy and Safety of Botulinum Neurotoxin Type A in Treating Chronic Low Back Pain: A Systematic Review, Meta‐Analysis, Trial Sequential Analysis, and Meta‐Regression. European Journal of Pain. 2025;29(4). doi:10.1002/ejp.4796

BibTeX
@article{Wagrees2025,
  author = {Wagrees, Waseem and Kelani, Hesham and Salamah, Hazem Mohamed and Mahmoud, Abdelrahman and Khlidj, Yehya and Abdelraouf, Mohamed R and Sharaf, Bahaa and Elnewishy, Moustafa and Albaramony, Nadia and Naeem, Ahmed and Elazim, Ahmed Abd and El-Ghanem, Mohammad and Greene-Chandos, Diana and Jadidi, Mohammad and Lerner, David P and Kay, Arthur D and Merlin, Lisa R and Brock, Charles},
  title = {The Efficacy and Safety of Botulinum Neurotoxin Type A in Treating Chronic Low Back Pain: A Systematic Review, Meta‐Analysis, Trial Sequential Analysis, and Meta‐Regression},
  journal = {European Journal of Pain},
  year = {2025},
  volume = {29},
  number = {4},
  doi = {10.1002/ejp.4796}
}
Kostenlos starten →